AR021876A1 - Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado - Google Patents

Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado

Info

Publication number
AR021876A1
AR021876A1 ARP990106462A ARP990106462A AR021876A1 AR 021876 A1 AR021876 A1 AR 021876A1 AR P990106462 A ARP990106462 A AR P990106462A AR P990106462 A ARP990106462 A AR P990106462A AR 021876 A1 AR021876 A1 AR 021876A1
Authority
AR
Argentina
Prior art keywords
interferon alfa
effective amount
weeks
hcv
therapeutically effective
Prior art date
Application number
ARP990106462A
Other languages
English (en)
Spanish (es)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR021876A1 publication Critical patent/AR021876A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP990106462A 1998-12-18 1999-12-16 Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado AR021876A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21587698A 1998-12-18 1998-12-18

Publications (1)

Publication Number Publication Date
AR021876A1 true AR021876A1 (es) 2002-08-07

Family

ID=22804768

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106462A AR021876A1 (es) 1998-12-18 1999-12-16 Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado

Country Status (7)

Country Link
EP (1) EP1140143A2 (de)
JP (1) JP2003507322A (de)
AR (1) AR021876A1 (de)
AU (1) AU2157000A (de)
CA (1) CA2354536A1 (de)
PE (1) PE20001369A1 (de)
WO (1) WO2000037110A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1736478B1 (de) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Verfahren und Zusammensetzungen zur Behandlung von Flaviviren und Pestiviren
DE60135393D1 (de) * 2000-06-30 2008-09-25 Zymogenetics Inc Allelische Variante des Interferon-ähnlichen Proteins Zcyto21
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
KR100851861B1 (ko) * 2000-08-07 2008-08-13 사이클론 파아머슈티컬 인코오퍼레이티드 티모신, 인터페론 및 리바비린을 사용한 씨 형 간염의치료
AU2002213343A1 (en) * 2000-10-18 2002-04-29 Schering Corporation Ribavirin-pegylated interferon alfa HCV combination therapy
EP1942187B1 (de) 2001-04-20 2010-09-22 ZymoGenetics, L.L.C. Zytokinproteinfamilie
US7910313B2 (en) 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
EP1435974A4 (de) 2001-09-28 2006-09-06 Idenix Cayman Ltd Verfahren und zusamemnsetzungen zur behandlung des hepatitis-c-virus mit 4'-modifizierten nucleosiden
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
LT1576138T (lt) 2002-11-15 2017-06-26 Idenix Pharmaceuticals Llc 2`-šakoti nukleozidai derinyje su interferonu ir flaviviridae mutacija
AU2003300901A1 (en) 2002-12-12 2004-06-30 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
HUE029877T2 (en) 2003-05-30 2017-04-28 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
JP2007501806A (ja) * 2003-08-13 2007-02-01 ハワード ジェイ． スミス アンド アソシエイツ ピーティーワイ エルティーディー ウィルス感染を治療する方法
CN101023094B (zh) 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
US8492539B2 (en) 2004-09-14 2013-07-23 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2489369A1 (de) * 2007-09-14 2012-08-22 Merck Sharp & Dohme Corp. Verfahren zur Behandlung von Patienten mit Hepatitis C
TW200946541A (en) 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
WO2010117936A1 (en) * 2009-04-06 2010-10-14 Schering Corporation Combinations of a hcv inhibitor such as bicyclic pyrrole derivatives and a therapeutic agent
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
EP2709613B2 (de) 2011-09-16 2020-08-12 Gilead Pharmasset LLC Verfahren zur behandlung von hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2583677A3 (de) 2011-10-21 2013-07-03 Abbvie Inc. Verfahren zur Behandlung von HCV mit wenigstens zwei direkt angreifenden viralen Mitteln, Ribavirin aber nicht Interferon.
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2950786B1 (de) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Kombinationsformulierung zweier antiviraler verbindungen
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ES2186660T3 (es) * 1997-09-21 2003-05-16 Schering Corp Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
AU766597B2 (en) * 1998-05-15 2003-10-16 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection

Also Published As

Publication number Publication date
EP1140143A2 (de) 2001-10-10
WO2000037110A2 (en) 2000-06-29
AU2157000A (en) 2000-07-12
JP2003507322A (ja) 2003-02-25
PE20001369A1 (es) 2000-12-09
CA2354536A1 (en) 2000-06-29
WO2000037110A3 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
CO4940414A1 (es) Terapia de interferones polietilenglicol modificados
NZ507621A (en) HCV-RNA eradication in antiviral treatment naive patients having HCV genotypes 1, 2 or 3 using ribavirin and interferon alpha combination therapy
ES2186660T3 (es) Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
RS20120201A3 (en) Methods and compositions for hepatitis c virus treatment
AR023541A1 (es) Terapia de combinacion para vhc
AR021226A1 (es) Terapia combinatoria con ribavirina-interferon alfa para erradicar el hcv-rna detectable en aquellos pacientes que presentan infeccion porhepatitis c cronica
TW200716095A (en) Method of treating interferon non-responders using HCV protease inhibitor
BR0114636A (pt) Terapia combinada para hcv de interferon-alfa peguilado/ribavirina
BR9911076A (pt) Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica
PL1778272T3 (pl) Zastosowanie kombinacji cyklosporyny i pegylowanych interferonów do leczenia zapalenia wątroby typu C (HCV)
EA201000085A1 (ru) dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
MD990258A (en) Method of treatment of the acute viral hepatitis B
MD2549F1 (en) Method of treatment of the chronic viral hepatitis C
CY1106388T1 (el) Θepαπεια ηπατιτιδας c με θυμοσινη, ιντepφepονη και ριβαβιρινη
JP2004529158A5 (de)
DK1311286T3 (da) Behandling af hepatitis C med thymosin og pegyleret interferon
ECSP993178A (es) Terapia combinatoria con ribarvirina -interferon alfa para erradicar el hcv - rna detectable en aquellos pacientes que presentan infeccion por hepatitis c cronica
TH33755A (th) การรักษาร่วมเพื่อขจัด hcv-rna ที่ตรวจหาได้ในผู้ป่วยที่ติดเชื้อตับอักเสบ c เรื้อรัง
TH53874A3 (th) การบำบัดรักษา hcv แบบผสมผสานโดยการเหนี่ยวนำด้วยไรบาไวรินและอินเทอฟีรอนอัลฟาชนิดเพกิเลเตด
FR2791894B1 (fr) Utilisation d'interferon beta dans le traitement de la tumeur d'ewing
TH87484A (th) Peg-ifn อัลฟา และริบาวิรินสำหรับรักษา hbv
ECSP982669A (es) Terapia en combinacion para erradicar vhc -arn detectable en pacientes que padecen infeccion de hetatitis c cronica

Legal Events

Date Code Title Description
FB Suspension of granting procedure